Arkansas 2023 Regular Session

Arkansas House Bill HR1063 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2	MAG026 2/1/2023 1:34:53 PM MAG026
3	3
4	4	State of Arkansas 1
5	5	94th General Assembly 2
6	6	Regular Session, 2023 HR 1063 3
7	7	4
8	8	By: Representative Painter 5
9	9	6
10	10	HOUSE RESOLUTION 7
11	11	A RESOLUTION RECOGNI ZING THE FIRST WEEK OF MAY 2023 8
12	12	AS TARDIVE DYSKINESI A AWARENESS WEEK IN ARKANSAS. 9
13	13	10
14	14	11
15	15	Subtitle 12
16	16	A RESOLUTION RECOGNIZING THE FIRST WEEK 13
17	17	OF MAY 2023 AS TARDIVE DYSKINESIA 14
18	18	AWARENESS WEEK IN ARKANSAS. 15
19	19	16
20	20	WHEREAS, many people who have a serious chronic mental illness such as 17
21	21	schizophrenia, bipolar disorder, or severe depression, or who have a 18
22	22	gastrointestinal disorder such as gastroparesis or symptoms such as nausea 19
23	23	and vomiting, require treatment with medications that work as dopamine 22 20
24	24	receptor blocking agents, including antipsychotics; and 21
25	25	22
26	26	WHEREAS, while ongoing treatment with these medications can be very 23
27	27	helpful and even lifesaving, it can also lead those undergoing treatment to 24
28	28	experience tardive dyskinesia; and 25
29	29	26
30	30	WHEREAS, tardive dyskinesia is a movement disorder characterized by 27
31	31	random, involuntary, and uncontrolled movements of muscles in the face, 28
32	32	trunk, and extremities; and 29
33	33	30
34	34	WHEREAS, tardive dyskinesia can develop months, years, or decades after 31
35	35	a person starts taking dopamine receptor blocking agents, even after he or 32
36	36	she has discontinued use of those medications, and is often permanent; and 33
37	37	34
38	38	WHEREAS, it is estimated that more than six hundred thousand (600,000) 35
39	39	Americans suffer from tardive dyskinesia, and the National Alliance on Mental 36 HR1063
40	40
41	41	2 2/1/2023 1:34:53 PM MAG026
42	42
43	43
44	44	Illness reports that one (1) in every four (4) patients receiving long -term 1
45	45	treatment with antipsychotic medication will experience tardive dyskinesia; 2
46	46	and 3
47	47	4
48	48	WHEREAS, tardive dyskinesia research has resulted in recent scien tific 5
49	49	breakthroughs, including two treatments approved by the United States Food 6
50	50	and Drug Administration; and 7
51	51	8
52	52	WHEREAS, tardive dyskinesia is often unrecognized, and patients 9
53	53	suffering from the disorder are sometimes misdiagnosed, leading the American 10
54	54	Psychiatric Association to recommend heightened awareness of and regular 11
55	55	screening for tardive dyskinesia in patients taking DRBAs; and 12
56	56	13
57	57	WHEREAS, Tardive Dyskinesia Awareness Week is recognized in many states 14
58	58	across the country during the first week of May each year, 15
59	59	16
60	60	NOW THEREFORE, 17
61	61	BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE NINETY -FOURTH GENERAL 18
62	62	ASSEMBLY OF THE STATE OF ARKANSAS: 19
63	63	20
64	64	THAT the House of Representatives recognize the first week of May 2023 as 21
65	65	Tardive Dyskinesia Awareness Week. 22
66	66	23
67	67	24
68	68	25
69	69	26
70	70	27
71	71	28
72	72	29
73	73	30
74	74	31
75	75	32
76	76	33
77	77	34
78	78	35
79	79	36